Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Clinical and translational results from the NEOSTAR study: Treating early-stage lung cancer with nivolumab plus ipilimumab

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.06.19
Views: 902

Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston, USA

Dr Tina Cascone talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the updated clinical and translational results of the NEOSTAR study.

The trial involved treating patients with early-stage, resectable non-small cell lung cancer in the neoadjuvant setting with nivolumab plus ipilimumab, using an endpoint of major pathologic response (MPR).

Dr Cascone explains that the rationale for the phase II multi-arm study is that more than 50 percent of patients in this group would be likely to relapse if treated with surgery alone, highlighting the importance of identifying the most effective approach with combination immune checkpoint inhibitors.

Find out more about this study here

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content. 

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation